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Abstract: LL-37, a cationic antimicrobial peptide, has numerous immune-modulating effects. 
However, the identity of a receptor that mediates the responses in immune cells remains uncer-
tain. We have recently demonstrated that LL-37 interacts with the a
M
I-domain of integrin a
M
b
2
 
(Mac-1), a major receptor on the surface of myeloid cells, and induces a migratory response 
in Mac-1-expressing monocyte/macrophages as well as activation of Mac-1 on neutrophils. 
Here, we show that LL-37 and its C-terminal derivative supported strong adhesion of vari-
ous Mac-1-expressing cells, including human embryonic kidney cells stably transfected with 
Mac-1, human U937 monocytic cells, and murine IC-21 macrophages. The cell adhesion to 
LL-37 was partially inhibited by specific Mac-1 antagonists, including monoclonal antibody 
against the a
M
 integrin subunit and neutrophil inhibitory factor, and completely blocked when 
anti-Mac-1 antibodies were combined with heparin, suggesting that cell surface heparan sulfate 
proteoglycans act cooperatively with integrin Mac-1. Coating both gram-negative and gram-
positive bacteria with LL-37 significantly potentiated their phagocytosis by macrophages, and 
this process was blocked by a combination of anti-Mac-1 monoclonal antibody and heparin. 
Furthermore, phagocytosis by wild-type murine peritoneal macrophages of LL-37-coated latex 
beads, a model of foreign surfaces, was several fold higher than that of untreated beads. In con-
trast, LL-37 failed to augment phagocytosis of beads by Mac-1-deficient macrophages. These 
results identify LL-37 as a novel ligand for integrin Mac-1 and demonstrate that the interaction 
between Mac-1 on macrophages and bacteria-bound LL-37 promotes phagocytosis.
Keywords: LL-37, integrin a
M
b
2
, Mac-1, CD11b/CD18, phagocytosis, opsonin
Introduction
LL-37, a member of the cathelicidin family of mammalian host defense peptides 
and the only representative of this group in humans, exerts numerous immune-
modulating effects in response to infections and other changes in the status of 
immune system.1   LL-37 is derived by a proteolytic cleavage in the C-terminal part 
of its precursor cationic antimicrobial protein-18 (hCAP-18) when this protein is 
secreted from cells during the immune-inflammatory response.2 While initially iso-
lated from neutrophils, hCAP-18/LL-37 has been subsequently found in other blood 
cells including monocyte/macrophages, eosinophils, natural killer cells, T-cells, and 
B-cells in addition to mast cells and various epithelial cells.3 The biological sig-
nificance of LL-37 in innate host defense has been established in the studies of its 
mouse homologue cathelicidin-related AMP (CRAMP), which shares with LL-37 
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similar gene structure and tissue  distribution: mice null for the 
CRAMP gene are more susceptible to streptococcal infections.4 
Furthermore, systemic expression of the hCAP-18/LL-37 
gene or LL-37 injection protects rodents from septic death.4–6
Similar to other antimicrobial cationic peptides, LL-37 
mainly consists of positively charged and hydrophobic 
residues and has a propensity to fold into the amphipathic 
a-helix in physiologically relevant buffers and environments 
mimicking biological membranes. The cationic and amphipa-
thic nature of antimicrobial peptides is generally associated 
with their bactericidal activity: the overall positive charge 
endows them with the ability to bind to the negatively charged 
bacterial wall and the anionic cell membrane.7,8 After inser-
tion into the membrane, antimicrobial peptides are thought 
to disrupt the integrity of the bilayer resulting in killing of 
bacteria. Although the direct bactericidal activity of LL-37 
has been documented in vitro under low salt conditions and 
in the absence of divalent cations such as Ca2+ and Mg2+, it 
is significantly reduced when assayed in physiologically rel-
evant media and at the peptide concentrations that are found 
at the sites of infection or inflammation.6 These observations 
led to an idea that the membrane-targeting activity of LL-37 
may not be the primary function of this peptide.6,9
Numerous studies have demonstrated that LL-37 exerts a 
multitude of effects on the immune cells in vitro.10,11 LL-37 has 
a chemotactic effect, acting upon and inducing migration of 
human peripheral blood monocytes, neutrophils, and T-cells.12 
It was shown to modulate the expression of hundreds of genes 
in monocytes and other cells, including those for chemokines 
and chemokine receptors.13 Human neutrophils exposed to 
LL-37 increase the production of reactive oxygen species14 
and exhibit delayed apoptosis.15 Thus, during infection, 
LL-37 released by degranulation of neutrophils or secreted 
from other cells would be expected to modulate the innate 
immune response through a variety of ways. However, the 
mechanisms underlying these LL-37 responses have not been 
well characterized, and to date, several receptors were reported 
to associate with LL-37-induced immunomodulation.12,16–19
We have recently characterized the recognition specific-
ity of integrin a
M
b
2
 (Mac-1, CD11b/CD18), a receptor with 
broad ligand-binding specificity expressed on neutrophils and 
monocyte/macrophages, and identified structural motifs pres-
ent in many Mac-1 ligands.20 In particular, the a
M
I-domain, 
a ligand-binding region of Mac-1, has affinity for short 6–9 
mer amino acid sequences containing a core of basic resi-
dues flanked by hydrophobic residues in which negatively 
charged residues are strongly disfavored. The binding motifs 
for Mac-1
 
can be coded as HyBHy, HyHyBHy, HyBHyHy, 
and HyHyBHyHy, where Hy represents any hydrophobic 
residue and B is either arginine or lysine. Other amino acids 
can also be found, but in general, their proportion within the 
Mac-1-binding motifs is very small. Inspection of the LL-37 
sequence revealed that it contains several putative Mac-1 rec-
ognition sites and may represent a ligand for Mac-1. Indeed, 
we have shown that recombinant a
M
I-domain bound several 
overlapping LL-37-derived peptides and the full-length 
LL-37 peptide that induced Mac-1-dependent migration of 
monocyte and macrophages as well as neutrophil activation.20
In this study, we have further examined the interaction of 
LL-37 with Mac-1-expressing cells. These studies were initiated 
to test the hypothesis that cationic LL-37, when deposited on the 
anionic bacterial surface, would serve as an adhesive ligand for 
Mac-1 on macrophages and promote phagocytosis. The results 
demonstrate that LL-37 is a potent opsonin that augments 
phagocytosis of both Gram-negative and Gram-positive strains 
through a cooperative binding of integrin Mac-1 and heparan 
sulfate proteoglycans (HSPGs) on the surface of macrophages.
Materials and methods
Peptides, proteins, and monoclonal 
antibodies
The  LL-37  pep t ide  ( 1LLGDFFRKSKEKIGKE-
FKRIVQRIKDFLRNLVPRTES37), its C-terminal part 
(residues 18–37; termed K18-37), and LL-37-GY containing 
two additional C-terminal residues Gly-Tyr were obtained 
from AnaSpec, Inc. (San Jose, CA, USA) and Peptide 2.0 
(Chantilly, VA, USA). Alternatively, recombinant LL-37 was 
prepared as described.21 Briefly, LL-37 was expressed as a 
fusion protein with glutathione S-transferase. The cDNA 
of LL-37 (from True Clone, Rockville, MD, USA) was 
cloned in the pGEX-4T-1 expression vector (GE  Healthcare, 
Chicago, IL, USA). Recombinant GST-LL-37 was purified 
from a soluble fraction of Escherichia coli lysates by affin-
ity chromatography using glutathione agarose. LL-37 was 
separated from GST by digestion with thrombin followed 
by gel filtration on Sephadex G-25. The isolated peptide 
was analyzed by Western blotting using polyclonal anti-
body sc-50423 (Santa Cruz Biotechnology Inc., Dallas, 
TX, USA). LL-37-GY was labeled with iodine-125 using 
IODO-GEN (Thermo Fisher Scientific, Waltham, MA, USA) 
to the specific activity of 6×109 cpm/mmol. Fibrinogen, 
depleted of fibronectin and plasminogen, was obtained from 
Enzyme Research Laboratories (South Bend, IN, USA). 
Recombinant a
M
I-domain (residues Glu123-Lys218) was 
prepared as described earlier.22 The monoclonal antibodies 
(mAbs) 44a, directed against the human a
M
 integrin sub-
unit, mAb IB4, against the human b
2 
integrin subunit, and 
mAb M1/70, against the mouse a
M
 subunit, were  purified 
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from the  conditioned media of hybridoma cells obtained 
from American Type Culture Collection (ATCC, Manassas, 
VA, USA) using protein A agarose. Mouse (G3A1) mAb 
IgG1 isotype control for mAb 44a was from Cell Signaling 
(Danvers, MA, USA) and rat IgG2b (MCA1125) isotype 
control for mAb M1/70 was from Bio-Rad Laboratories Inc. 
(Hercules, CA, USA). The anti-b
1
 mAb AIIB2 was from 
Developmental Studies Hybridoma Bank (Iowa City, IA, 
USA). Bovine serum albumin (BSA), polyvinylpyrrolidine, 
heparin (sodium salt; from porcine intestinal mucosa), and 
poly-l-lysine (molecular weight 90,000 Da) were obtained 
from Sigma-Aldrich Co. (St Louis, MO, USA). MC 4501, 
and fluorescent latex beads (FluoroSpheres, 1 mm) were 
from Thermo Fisher Scientific.
Synthesis of cellulose-bound peptide 
libraries
The FALL-39-derived peptide library assembled on a single 
cellulose membrane support was prepared by parallel spot 
synthesis as described earlier.23,24 The membrane-bound 
peptides were tested for their ability to bind the a
M
I-domain 
according to a procedure described earlier.23 In brief, the 
membrane was blocked with 1% BSA and then incubated 
with 10 mg/mL of 125I-labeled a
M
I-domain in Tris-buffered 
saline containing 1 mM MgCl
2
. After washing, the membrane 
was dried, and the a
M
I-domain binding was visualized by 
autoradiography.
Cells
Human embryonic kidney cells (HEK293) and HEK293 
cells stably expressing integrin Mac-1 were described ear-
lier.25,26 The cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (Mediatech Inc., Manassas, VA, USA) 
supplemented with 10% fetal bovine serum (FBS) and 
antibiotics. U937 human monocytic cells were grown in 
Roswell Park Memorial Institute (RPMI) containing 10% 
FBS and antibiotics. The THP-1 human monocytic cell line 
was purchased from ATCC and cultured in RPMI containing 
10% FBS, antibiotics, and 0.05 mM 2-mercaptoethanol. The 
THP-1 cells were differentiated into macrophages by adding 
10 ng/mL of phorbol 12-myristate 13-acetate (PMA) into the 
medium for 48 hours as described earlier.27 The IC-21 murine 
macrophage cell, Staphylococcus aureus subsp. aureus 25923 
(ATCC 25923) and E. coli MG-1655 (ATCC 700926) were 
from ATCC. Resident peritoneal leukocytes were obtained 
from 8-week-old wild-type C57BL/6 and Mac-1-/- mice 
(The Jackson Laboratories, Bar Harbor, ME, USA) by lavage 
using cold phosphate-buffered saline (PBS)  containing 
5 mM EDTA. The  population of  wild-type leukocytes 
contained 46.3%±2.7% and 44.1%±3.6% of macrophage 
and lymphocytes, respectively, and that obtained from Mac-
1-/- mice consisted of 37.3% macrophages and 53%±2.9% 
lymphocytes. Macrophages were obtained by plating a total 
population of peritoneal leukocytes on glass cover slides 
for 2 hours at 37°C in 5% CO
2
 followed by the removal of 
nonadherent cells (mainly lymphocytes) that resulted in the 
enrichment of adherent macrophages.
Cell adhesion assays
Adhesion assays were performed essentially as described 
earlier.25,26 Briefly, the wells of 96-well microtiter plates 
(Immulon 4HBX; Thermo Labsystems, Franklin, MA, 
USA) were coated with various concentrations of LL-37- or 
LL-37-derived peptides for 3 hours at 37°C and postcoated 
with 1.0% PVP for 1 hour at 37°C. Fibrinogen was coated 
at 2.5 mg/mL. Cells were labeled with 5 μM calcein for 
30 minutes at 37°C and washed twice with Hanks’ balanced 
salt solution containing 0.1% BSA. Aliquots (100 μL) 
of labeled cells (5×105/mL) were added to each well and 
allowed to adhere for 30 minutes at 37°C. The nonadherent 
cells were removed by two washes with PBS. Fluorescence 
was measured in a CytoFluorII fluorescence plate reader 
(Thermo Fisher Scientific). In inhibition experiments, cells 
were mixed with different concentrations of mAbs, neutro-
phil inhibitory factor (NIF), heparin, or the K18-37 peptide 
for 15 minutes at 22°C before they were added to the wells 
coated with adhesive substrates.
Phagocytosis assays
A suspension of fluorescein-labeled S. aureus particles 
(4×107/mL) (pHrodo® Green; Thermo Fisher Scientific) 
was incubated with different concentrations of LL-37 or 
K18-37 for 20 minutes at 22°C, and then unbound peptide 
was removed by centrifugation. IC-21 murine macrophages 
(106/mL) were mixed with peptide-coated S. aureus particles. 
After incubating for 60 minutes at 37°C, nonphagocytosed 
of S. aureus particles were separated from macrophages by 
filtering the suspension using Transwell inserts with a pore 
size of 3.0 μm (Costar; Corning Incorporated, Corning, NY, 
USA). Macrophages were transferred to the wells of 96-well 
microtiter plates, and trypan blue (0.2%) was applied to 
wells to quench the fluorescence of any remaining S. aureus 
outside of macrophages. The ratio of bacterial particles per 
macrophage was quantified taking photographs of three fields 
for each well using a Leica DM4000 B microscope (Leica 
Microsystems, Wetzlar, Germany) with a 20× objective.
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Phagocytosis by adherent macrophages was performed 
using fluorescein isothiocyanate (FITC)-labeled bacteria. To 
label E. coli, bacteria were grown overnight and diluted with 
50 mM NaHCO
3
, pH 8.5 to OD =1.5. FITC was dissolved in 
dimethyl sulfoxide and added to 0.5 mL E. coli suspensions 
to a final concentration of 0.1 mg/mL. Suspensions were 
incubated for 1 hour at 22°C. Labeled bacteria were washed 
four times with 4×1 mL PBS by centrifugation at 1,800× 
g for 5 minutes. FITC-labeled E. coli (100 mL, 3×108 par-
ticles/mL) were incubated with LL-37 for 30 minutes at 
37°C and washed with RPMI by centrifugation at 1,800× 
g for 5 minutes to remove unbound peptide. The pellet was 
resuspended in RPMI +10% FBS at the concentration of 
107 bacterial particles/mL. For control experiments, media 
were substituted for LL-37, but all other aspects of the pro-
cedure were the same. For selected experiments, fluorescent 
1.0 mM latex beads were incubated with LL-37, washed, and 
applied at 2.5×106 to wells containing macrophages. IC-21 
murine macrophages, macrophages isolated from the mouse 
peritoneum, and differentiated THP-1 human macrophages 
were resuspended in RPMI +10% FBS and cultured in Costar 
48-well plates (2.5×105/well) for 3–5 hours at 37°C. After 
the media were aspirated, adherent cells were washed and 
incubated with 0.5 mL FITC-labeled E. coli suspensions, 
S. aureus particles, or fluorescent latex beads for 1 hour at 
37°C. Cells were washed three times with 3×1 mL PBS, and 
phagocytosed bacteria or beads were counted in the presence 
of trypan blue.
In comparative studies of LL-37-induced phagocytosis 
by macrophages isolated from the peritoneum of wild-type 
and Mac-1-/- mice, the cells were allowed to adhere to glass 
cover slides for 2 hours at 37°C. After removing nonadher-
ent cells, fluorescent latex beads treated with LL-37 were 
added to the cells and incubated for 30 minutes at 37°C. 
Cells were washed with PBS, fixed with 2% paraformalde-
hyde, and beads counted. Animal studies were carried out 
in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol was approved by the Institu-
tional Animal Care and Use Committee of the Arizona State 
University (protocol number 13-1271R) and Mayo Clinic in 
Arizona (protocol number A22313).
Statistical analysis
All data are presented as the mean ± standard error. The 
statistical differences between two groups were determined 
using a Student’s t-test from SigmaPlot 11.0 software (Systat 
Software, San Jose, CA, USA). For multiple comparisons, 
the Bonferroni correction method was used. Differences were 
considered significant at P<0.05.
Results
Analyses of the aMI-domain-binding 
capacity of the FALL-39-derived peptides
We previously screened a small peptide library consisting 
of eleven 9-mer peptides spanning the sequence of LL-37 
for binding of recombinant a
M
I-domain.20 A remarkable 
feature of LL-37 is that ten overlapping peptides that 
bound the a
M
I-domain formed a continuous stretch. To 
validate these data, we synthesized an additional library 
spanning the sequence of FALL-39, an active derivative 
of LL-37, which includes the sequence of LL-37 and two 
additional N-terminal residues Phe and Ala present in the 
hCAP-18 cathelin precursor (Figure 1A).28 Similar to the 
FALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Lys18
Arg19
Arg23
Lys25 Arg29
Ile20
Ile24
Phe27
Arg34
A
B Energy,
J/mol 
Densitometry, 
%
Sequence
–1,395
–4,333
–10,377
–918
–4,634
–5,677
–15,506
–3,501
–6,915
–3,636
–3,196
0
70
70
95
30
50
60
100
55
70
80
30
1. FALLGDFFR
2. LDDFFRKSK
3. FFRKSKEKI
4. KSKEKIGKE
5. EKIGKEFKR
6. GKEFKRIVQ
7. FKRIVQRIK
8. IVQRIKDFL 
9. RIKDFLRNL
10.DFLRNLVPR
11.RNLVPRTES
12.Control
Figure 1 Characterization of the aMI-domain recognition motifs in the FALL-39 
sequence.
Notes: (A) The amino acid sequence of FALL-39 and the 3D structure of LL-37 
based on PDB Id: 2K6O. Positively charged (blue) and hydrophobic (tan) residues 
in the C-terminal part of the peptide are numbered. The underlined sequences 
denote the aMI-domain recognition patterns. (B) The peptide library derived from 
the FALL-39 sequence (left panel) consisting of 9-mer peptides with a three-residue 
offset was incubated with 125I-labeled aMI-domain, and the aMI-domain binding was 
visualized by autoradiography. Control – a spot containing only the b-Ala spacer 
used for the attachment of peptides to the cellulose membrane. The aMI-domain 
binding observed as dark spots was analyzed by densitometry (middle column). The 
numbers show the relative binding of the aMI-domain to peptides expressed as a 
percentage of the intensity of spot 3. The peptide energies (right column) that serve 
as a measure of probability each peptide can interact with the aMI-domain were 
calculated as described.20
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LL-37 library, all overlapping peptides in the FALL-39 
scan bound the a
M
I-domain. Densitometric analyses of the 
library indicated that the most active peptides were present in 
spots 3 and 6 (Figure 1B). The a
M
I-domain-binding peptides 
were analyzed by a previously developed algorithm, which 
determines the capacity of each peptide to interact with the 
a
M
I-domain.20 The program assigns each peptide the energy 
value that serves as a measure of probability that the a
M
I-
domain binds this sequence: the lower the energy, the higher 
the likelihood that the sequence binds the a
M
I-domain. As 
determined from the analyses of numerous Mac-1 ligands, 
the peptides that strongly bind a
M
I-domain have energy 
values in the range of -20 kJ/mol to 2 kJ/mol.20 Based on 
the application of the algorithm, all peptides in the FALL-39 
library had energies between -15.5 kJ/mol and -0.9 kJ/mol 
(Figure 1B). Moreover, the two most active peptides in spots 
3 and 6 had the lowest energies. The finding that overlap-
ping peptides in the library form a continuous stretch con-
taining strong a
M
I-domain recognition cores 5FFRKSK10, 
12KIGK15, 17FKRIVQRIK25, and 27FLRNLVPR34 in which 
basic residues are surrounded or flanked by hydrophobic 
residues suggests that FALL-39 and LL-37 have the strong 
a
M
I-domain-binding potential.
LL-37 supports adhesion of the 
Mac-1-expressing HEK293 cells
The interaction of the a
M
I-domain with LL-37-derived 
peptides suggests that LL-37 may support adhesion of 
Mac-1-expressing cells. To investigate this possibility, we 
performed adhesion with immobilized LL-37 using vari-
ous Mac-1-expressing cells. As shown in Figure 2A, LL-37 
supported efficient adhesion of a model HEK293 cell line 
genetically engineered to stably express integrin Mac-1 
(Mac-1-HEK293 cells)
.
 Cell attachment was dose dependent 
with saturable adhesion occurring at a coating concentra-
tion of 2 mg/mL. At this concentration, 52%±5% of added 
cells adhered to LL-37 (n=6). Using 125I-labeled LL-37-GY, 
we verified that peptide was immobilized on plastic in a 
concentration-dependent manner and supported adhesion 
(Figure S1). By contrast, no adhesion of wild-type HEK293 
cells in the range of 0–1.0 μg/mL coating concentrations of 
LL-37 was observed (Figure 2A). At higher coating concen-
trations (1–4 μg/mL), LL-37 supported adhesion of wild-type 
HEK293 cells; however, maximal adhesion did not reach 
the level attained with Mac-1-HEK293 cells (Figure 2A). 
Human monocytic U937 cells naturally expressing Mac-1 
also adhered to LL-37 in a concentration-dependent man-
ner (data not shown). The role of Mac-1 in the interaction 
of Mac-1-HEK293 cells with LL-37 was determined using 
function-blocking mAb 44a directed to the human a
M
 integrin 
subunit. mAb 44a inhibited adhesion of the Mac-1-HEK293 
cells by ~90% at the low (0.4 mg/mL) coating concentrations 
of LL-37 (Figure 2B, middle panel). An isotype control IgG1 
for mAb 44a was not active. At higher coating concentra-
tions of LL-37, mAb 44a was less effective: at 0.5 mg/mL of 
LL-37, it inhibited adhesion by ~20% (data not shown), and 
at 2 mg/mL, it produced only ~5% inhibition (Figure 2B, right 
panel). The role of Mac-1 in mediating adhesion to LL-37 
was also examined using NIF, a specific inhibitor of the a
M
I-
domain–ligand interactions.29 As seen with mAb 44a, NIF 
effectively blocked adhesion of the Mac-1-HEK293 cells to 
the low (0.4 mg/mL), but not high (≥2 mg/mL) concentrations 
of LL-37 (Figure 2B). Partial inhibition of cell adhesion 
by specific anti-Mac-1 reagents and the fact that wild-type 
HEK293 cells were capable of mediating adhesion to LL-37 
suggest that other receptors and/or cell structures contribute 
to cell attachment to LL-37.
It is well known that several integrins, including Mac-1, 
cooperate with cell surface HSPGs during cell adhesion to the 
extracellular matrix proteins.30,31 LL-37 is a highly positively 
charged molecule and is expected to bind negatively charged 
HSPGs. To investigate whether HSPGs on wild-type and 
Mac-1-HEK293 cells are required for cell adhesion to LL-37, 
we examined the effect of heparin. Heparin at 20 mg/mL was 
a strong inhibitor of adhesion of wild-type HEK293 cells at 
all coating concentrations of LL-37 (Figure 2B). We also 
considered that b
1
 integrins, the major type of integrins on the 
surface of these cells,26 may contribute to LL-37 recognition. 
However, we found no significant effect of anti-b
1
 mAb alone 
or in combination with heparin, suggesting that on the surface 
of wild-type HEK293 cells, HSPGs are mainly involved in 
LL-37 binding (Figure 2B). With the Mac-1-HEK293 cells, 
heparin effectively inhibited cell adhesion to wells coated 
with the low concentration of LL-37 (0.4 mg/mL), and both 
anti-a
M
 mAb 44a and heparin completely blocked adhesion 
(Figure 2B). However, heparin was much less effective in 
blocking cell adhesion to the high (2 mg/mL) coating con-
centration of LL-37 (Figure 2B). Nevertheless, when cells 
were treated with both mAb 44a and heparin, cell adhesion 
was inhibited by >95%.
Consistent with the role of Mac-1 in adhesion to LL-37, 
Mac-1-HEK293 cells spread in a concentration-dependent 
manner with the formation of stress fibers, as detected by 
staining for actin with Alexa Fluor 546-conjugated phalloidin 
(Figure 2C, upper panel). By contrast, wild-type HEK293 
cells remained round when plated on slides coated with the 
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low concentrations of LL-37 (0.2–1.0 μg/mL) and spread at 
higher LL-37 concentrations (2 μg/mL). However, their mor-
phology was entirely different from that of Mac-1-HEK293 
cells with many actin-based filopodia/microspikes formed at 
the cell periphery (Figure 2C, bottom panel). Together, these 
results identify LL-37 as an adhesive ligand for Mac-1 and 
indicate that on the surface of Mac-1-HEK293 cells, Mac-1 
and HSPGs are involved in LL-37 recognition. They further 
suggest that the engagement of LL-37 by Mac-1 during adhe-
sion transduces intracellular signaling, leading to assembly 
of the actin cytoskeleton.
The C-terminal LL-derived peptide 
K18-37 supports and inhibits adhesion of 
Mac-1-expressing HEK293 cells
To investigate whether the C-terminal part of LL-37, 
18KRIVQRIKDFLRNLVPRTES37, previously reported to be 
mainly responsible for the antimicrobial effect of LL-37,2,32 
was involved in supporting adhesion, we examined dose 
dependency of adhesion of Mac-1-HEK293 cells to the K18-
37 peptide. As shown in Figure 3A, K18-37 supported effi-
cient cell adhesion. Adhesion was concentration dependent, 
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Figure 2 LL-37 supports adhesion of the aMb2-expresing cells.
Notes: (A) Aliquots (100 mL; 5×104/mL) of Mac-1-expressing HEK293 (Mac-1-HEK293) and wild-type HEK293 (HEK293) cells labeled with calcein were added to microtiter 
wells coated with different concentrations of LL-37 and postcoated with 1% PVP. After 30 minutes at 37°C, nonadherent cells were removed by washing and fluorescence 
of adherent cells was measured in a fluorescence reader. A representative of six experiments in which two cell lines were tested side by side is shown. Data presented are 
means for triplicate determinations, and error bars represent SE. Fluorescence is expressed in arbitrary units (a.u.). (B) Wild-type HEK293 cells were preincubated with 
anti-b1 mAb (10 mg/mL), heparin (20 mg/mL) or their mixture for 15 minutes at 22°C and added to wells coated with 2 mg/mL LL-37. Mac-1-HEK293 cells were preincubated 
with anti-aM mAb 44a (10 mg/mL), heparin (20 mg/mL) or their mixture and added to wells coated with 0.4 mg/mL or 2 mg/mL LL-37. Adhesion in the absence of Mac-1 
inhibitors and heparin was assigned a value of 100%. Data shown are mean ± SE from three to four separate experiments with triplicate measurements. *P≤0.05 and **P≤0.01 
compared with control adhesion in the absence of inhibitors. (C) Mac-1-HEK293 (upper panel) and HEK293 cells (bottom panel) were plated on glass slides and allowed 
to adhere for 30 minutes at 37°C. Nonadherent cells were removed and adherent cells were fixed with 2% paraformaldehyde followed by staining with Alexa Fluor 546 
phalloidin. The cells were imaged with a Leica SP5 laser scanning confocal microscope with a 63× objective.
Abbreviations: PVPV, polyvinylpyrrolidine; SE, standard error.
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and at 5 μg/mL, 47%±7% of added cells adhered to peptide 
(maximal adhesion). We next evaluated the effect of soluble 
K18-37 on adhesion of Mac-1-HEK cells to immobilized 
fibrinogen, a well-established Mac-1 ligand. It has been 
reported that a
M
I-domain-binding peptides derived from 
different ligands inhibit Mac-1-mediated adhesion to the 
fibrinogen-derived D fragment,20 which contains the g383MKI-
IPFNRLTIG395 sequence, the prototype adhesive sequence for 
the a
M
I-domain.33,34 As shown in Figure 3B, preincubation 
of cells with soluble K18-37 dose dependently inhibited cell 
adhesion with an half maximal inhibitory concentration (IC
50
) 
of 6 mg/mL, indicating mutual exclusive binding of K18-37 
to the a
M
I-domain. Control peptide DIDPKLKWD (11.1 kJ/
mol) was inactive. Previous studies demonstrated that soluble 
LL-37 affects the membrane integrity of leukocytes, albeit at 
the high concentrations (>50 mg/mL).35,36 We reasoned that 
if soluble K18-37 also damaged the membrane, it would 
result in the leakage of calcein and decreased fluorescence of 
adherent cells, giving a false impression of reduced adhesion. 
Therefore, in control experiments, we examined the effect 
of K18-37 by determining the leakage of calcein loaded into 
the Mac-1-HEK cells. As shown in Figure 3B (left ordinate), 
peptide was not active even at 50 mg/mL. Thus, inhibition of 
cell adhesion by K18-37 is unlikely due to its effect on the 
cell membrane.
Adhesion of mouse macrophages to the 
K18-37 peptide is partly mediated by 
Mac-1 and HSPGs
The human LL-37 peptide has been shown to exert its 
immunomodulatory effects across a wide range of species, 
including mouse, rat, rabbit, and human.13,37,38 Therefore, 
we examined the ability of LL-37 and K18-37 to support 
the adhesion of the murine macrophage cell line IC-21. 
Macrophages strongly adhered to LL-37 and K18-37 
 (Figure 4A, shown for K18-37). A similar pattern of inhi-
bition by anti-a
M
 antibodies that has been observed with 
human Mac-1-HEK293 cells was detected with IC-21 
macrophages, that is, while mAb M1/70 against the murine 
a
M
 integrin subunit was a strong inhibitor of adhesion at the 
low coating concentrations of peptide (>90% inhibition at 
0–0.5 mg/mL), it gradually lost its blocking potency as the 
coating concentration increased (Figure 4A). At 2 μg/mL 
of K18-37, mAb M1/70 inhibited adhesion by 46%±9% 
 (Figure 4B). An isotype control IgG2b for mAb M1/70 had no 
significant effect. Pretreatment of cells with heparin (20 μg/
mL) resulted in only partial inhibition of adhesion at both 
low (0.5 μg/mL) and high (2 μg/mL) coating concentrations 
of K18-37 (25%±13% and 32%±12%; Figure 4B). Pretreat-
ment of cells with both mAb M1/70 and heparin resulted in 
the complete inhibition of adhesion only at the low, but not 
high concentrations of K18-37 (Figure 4B). These results 
suggest that on the surface of IC-21 macrophages, Mac-1 
and HSPGs are involved in adhesion to K18-37; however, 
other receptors and/or glycosaminoglycans may participate 
in peptide binding.
The interaction of LL-37 with bacteria 
enhances phagocytosis by macrophages 
via Mac-1 and HSPGs
Since LL-37 supported efficient cell adhesion, we ques-
tioned whether LL-37 deposited on the bacterial surface 
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Figure 3 Adhesion of Mac-1-HEK293 and wild-type HEK293 cells to the LL-37-derived peptide K18-37. 
Notes: (A) Aliquots (100 mL; 5×104/mL) of Mac-1-HEK293 cells were labeled with calcein and added to microtiter wells coated with different concentrations of K18-37. 
After 30 minutes at 37°C, nonadherent cells were removed and adhesion was measured. Adhesion was expressed as percent of added cells. The data shown are mean and 
SE from four experiments with triplicate determinations at each point. (B) Calcein-labeled Mac-1-HEK293 cells were incubated with different concentrations of K18-37 (·) 
or control peptide () for 15 minutes at 22°C and added to wells coated with 2.5 mg/mL fibrinogen and postcoated with 1% PVP. Adhesion (left ordinate) was determined 
after 30 min. Right ordinate, Mac-1-HEK293 cells were treated with different concentrations of K18-37 for 15 minutes at 22°C. Cells were centrifuged and fluorescence of 
cell supernatants determined (). The data shown are the mean ± SE from two experiments each with triplicate determinations.
Abbreviations: SE, standard error; PVP, polyvinylpyrrolidine.
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can serve as an adhesive ligand for Mac-1 on macrophages, 
thereby promoting bacterial phagocytosis. We first assessed 
the binding capacities of representative gram-negative and 
gram-positive bacteria for LL-37 and compared them with 
several mammalian cells. As shown in Figure 5, U937, 
IC-21, and erythrocytes bound significantly less 125I-labeled 
LL-37-GY than the tested bacteria. At 5 mg/mL of soluble 
peptide, the binding capacity of E. coli was 1.4±0.1 fg/mm2 
similar to that of the plastic used in adhesion experiments. 
While Salmonella bound 1.8-fold less LL-37 than E. coli, 
the quantity of bound peptide was still ~17-fold higher 
than that associated with mammalian cells. The differential 
binding capacity of LL-37 is in agreement with the previ-
ously discussed characteristics that distinguish bacterial and 
mammalian cell membranes.8,39 These results suggest that 
the high density of LL-37 bound to the bacterial surface may 
support macrophage attachment.
To assess whether LL-37 influences phagocytosis of bac-
teria by macrophages, suspensions of fluorescein-labeled S. 
aureus particles and E. coli were incubated with LL-37. After 
the removal of nonbound peptide, the coated bacteria were 
incubated with IC-21 macrophages for 60 minutes at 37°C 
with the subsequent removal of nonphagocytosed particles. 
Before photographing the phagocytosed cells, trypan blue 
was added to quench the fluorescence of the remaining extra-
cellular-bound bacterial particles. As shown in  Figure 6A and 
B, treatment of S. aureus with 5 mg/mL of LL-37 significantly 
augmented phagocytosis by macrophages. The C-terminal 
K18-37 peptide was also active in enhancing phagocytosis 
of S. aureus particles (Figure 6A). Moreover, the effect of 
LL-37 was dose dependent and saturable at 10 mg/mL (Figure 
6C, shown for E. coli).
To investigate whether integrin Mac-1 and HSPGs on 
macrophages are involved in promoting phagocytosis of LL-
37-coated bacteria, we examined the effects of anti-a
M
 mAb 
M1/70 and heparin. On its own, mAb M1/70 did not inhibit 
LL-37-mediated phagocytosis (Figure 6D). In addition, 
heparin only slightly decreased the number of phagocytosed 
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Figure 4 Adhesion of murine IC-21 macrophages to the LL-37-derived peptide K18-37. 
Notes: (A) Calcein-labeled IC-21 macrophages were preincubated for 15 minutes at 22°C with buffer (·) or 10 µg/mL mAb M1/70 (anti-aM) (). Aliquots (5×104/0.1 mL) 
of cells were added to microtiter wells coated with different concentrations of K18-37 (0–2 µg/mL) and postcoated with 1% PVP. After 30 minutes at 37°C, nonadherent 
cells were removed by washing and adhesion was determined. (B) IC-21 macrophages were preincubated with anti-aM mAb M1/70 (10 mg/mL), heparin (20 µg/mL) or 
their mixture and added to wells coated with 0.5 mg/mL and 2 mg/mL K18-37. Adhesion in the absence of inhibitors and heparin was assigned a value of 100%. The data 
shown are the mean ± SE from five to six experiments each with triplicate determinations. *P≤0.05 and **P≤0.01 compared with control adhesion in the absence of 
inhibitors.
Abbreviations: PVP, polyvinylpyrrolidine; SE, standard error.
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20 minutes at 22°C. Nonbound peptide was removed by centrifugation at 
200 g (mammalian cells) or 2,000 g (bacteria) for 10 minutes. The pellet was 
washed with PBS, resuspended in 100 µL PBS and radioactivity was measured. 
The data shown are the mean ± SE from three experiments each with duplicate 
measurements.
Abbreviations: PBS, phosphate-buffered saline; SE, standard error; E. coli, 
Escherichia coli.
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Figure 6 Effect of LL-37 on phagocytosis of S. aureus particles and E. coli by suspensions of murine IC-21 macrophages.
Notes: (A) Fluorescent S. aureus particles (4×107/mL) were preincubated with LL-37 (5 mg/mL), K18-37 (10 µg/mL), or poly-l-lysine (10 µg/mL) for 20 minutes at 22°C. 
Soluble peptide was removed by centrifugation. Peptide-coated particles were incubated with suspensions of IC-21 macrophages (106/mL) for 60 minutes at 37°C, and 
nonphagocytosed particles were separated from cells by filtering the suspensions using 3 mm pore transwell inserts. Macrophages were transferred to wells of 96-well plates, 
and trypan blue was added to the wells. The ratio of bacterial particles per macrophage was quantified for five random fields per well using a 20× objective. Data are mean ± 
SE per cell from five or more experiments. **P≤0.01 compared with untreated control S. aureus. (B) Bright field (a and e), fluorescence (b and f), and merged (c and g) images 
of IC-21 macrophages incubated with LL-37-coated (a–c) or uncoated (e–g) control bacteria. The representative low power (20×) fields are shown. Enlarged images (d and h) 
of macrophages shown in the boxed areas in c and g. Phagocytosed bacterial particles are labeled in green. (C) Concentration-dependent effect of LL-37 on phagocytosis of E. 
coli by macrophages. Fluorescently labeled E. coli cells were incubated with different concentrations of LL-37 for 20 minutes at 22°C. After the removal of nonbound peptide 
by centrifugation, LL-37-coated E. coli were incubated with IC-21 macrophages (106/mL) for 60 minutes at 37°C. Data are expressed as mean ± SE of ratios of bacteria per 
macrophage. A representative of three experiments is shown. (D) Fluorescent S. aureus particles were preincubated with LL-37 (5 mg/mL) for 20 minutes at 22°C. Soluble 
peptide was removed by centrifugation. Peptide-coated bacterial particles were incubated with IC-21 macrophages (106/mL) in the presence of anti-aM mAb M1/70 (20 mg/
mL), heparin (20 mg/mL), or their mixture. After 60 minutes incubation at 37°C, nonphagocytosed S. aureus particles were removed, and phagocytosis was determined. Data 
shown are mean ± SE of bacterial particles per cell of five random fields determined for each condition and are representative of three separate experiments. *P≤0.05 and 
**P≤0.01.
Abbreviations: S. aureus, Staphylococcus aureus; E. coli, Escherichia coli; SE, standard error.
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bacterial particles. However, when macrophages were incu-
bated with LL-37-coated particles in the presence of M1/70 
and heparin, the ability of peptide to boost phagocytosis was 
diminished by ~70%, consistent with the blocking effect of 
these reagents on cell adhesion. It should be noted that since 
the combination of heparin and anti-Mac-1 mAb did not 
produce complete inhibition, other receptors on IC-21 mac-
rophages may contribute to LL-37-mediated phagocytosis.
Since positively charged residues in LL-37 are involved in 
the interaction with Mac-1 and HSPGs on macrophages, we 
examined whether other positively charged compounds can 
enhance phagocytosis. It is well known that poly-l-lysine sup-
ports cell adhesion, and this interaction is completely abolished 
by heparin. Therefore, we examined the effect of poly-l-lysine 
on phagocytosis of bacterial particles. No enhancement of 
phagocytosis by IC-21 macrophages of poly-l-lysine-coated 
particles was detected (Figure 6A), indicating that the pres-
ence of basic residues alone is not sufficient for promoting 
phagocytosis, while underscoring the requirement for a specific 
signal provided by Mac-1 recognition motifs present in LL-37.
The effect of LL-37 (5 mg/mL) on phagocytosis of bacte-
ria by adherent macrophages was also examined. As shown 
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in Figure 7A and B, phagocytosis of E. coli and S. aureus by 
adherent IC-21 macrophages increased by ~17- and 10-fold, 
respectively. In addition, LL-37 increased phagocytosis of 
E. coli and S. aureus by adherent murine peritoneal macro-
phages (Figure 7A, shown for E. coli). Thus, LL-37 is capable 
of boosting phagocytosis of bacterial cells by both adherent 
and nonadherent macrophages.
LL-37 augments phagocytosis of plastic 
beads via Mac-1
Its high affinity for plastic suggests that LL-37 may promote 
phagocytosis of foreign bodies. To examine this  possibility, we 
tested the ability of LL-37 to enhance phagocytosis of latex 
beads. Preliminary experiments using 125I-labeled LL-37-GY 
showed that at 10 mg/mL, peptide readily bound to the surface 
of beads (10.6±1.3 fg/mm2). Control and LL-37-treated fluo-
rescent 1 mm beads were incubated with various cells, includ-
ing IC-21 macrophages, peritoneal mouse macrophages, 
and human THP-1 cells at a ratio of 10:1 for 30 minutes 
(a saturation time determined in preliminary experiments), 
and their phagocytosis was determined (Figure 8A and B). 
Quantification of phagocytosed beads indicated that LL-37 
augmented uptake by ~3.5-, 4.5-, and 6-fold by IC-21, peri-
toneal macrophages, and THP-1 cells, respectively.
Figure 7 Augmentation of phagocytosis of LL-37-coated bacteria by adherent macrophages.
Notes: (A) Fluorescently labeled S. aureus particles and E. coli cells were incubated with LL-37 (5 mg/mL) for 20 minutes at 22°C. Soluble peptide was removed by 
centrifugation and LL-37-coated bacteria were subsequently incubated with adherent IC-21 macrophages or mouse peritoneal macrophages for 60 minutes at 37°C. Data are 
expressed as mean ± SE of ratios of bacteria per macrophage. The panels shown in (A) are representative of three or more experiments. **P≤0.01 compared with untreated 
control bacteria. (B) A representative experiment showing bright field (a and e), fluorescence (b and f), and merged images (c and g) of IC-21 macrophages exposed to LL-
37-coated and uncoated control S. aureus. "d" and "h" enlarged images of boxed areas shown in "c" and "g", respectively.
Abbreviations: S. aureus, Staphylococcus aureus; E. coli, Escherichia coli; SE, standard error.
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Further evidence supporting the role of Mac-1 in LL-
37-induced phagocytosis was obtained using macrophages 
isolated from the peritoneum of wild-type and Mac-1-/- mice. 
Control and LL-37-coated fluorescent beads were added to 
adherent wild-type and Mac-1-deficient macrophages for 
30 minutes at 37°C, and their phagocytosis was determined. 
In agreement with previous data that phagocytosis of Mac-
1-deficient neutrophils is impaired,40,41 phagocytosis of 
control beads by Mac-1-deficient macrophages was strongly 
reduced (Figure 9A–C). Pretreatment of beads with LL-37 
enhanced their uptake by wild-type macrophages by ~5 times. 
Phagocytosis of LL-37-coated beads by Mac-1-deficient 
macrophages was also increased; however, LL-37 failed to 
enhance phagocytosis to the level observed with wild-type 
macrophages (Figure 9D). These data suggest that on the 
 surface of macrophages, Mac-1 is the major receptor respon-
sible for the opsonic function of LL-37.
Discussion
Several mechanisms have been proposed that may account 
for the ability of the cathelicidin peptide LL-37 to protect the 
host from infections, including direct pathogen killing and 
eliciting numerous responses from the immune and other host 
cells. The immunomodulatory effects of LL-37 have been 
ascribed to its binding to and/or modulating activity of sev-
eral unrelated cell surface receptors such as FPRL 1, EGFR, 
P2X
7
, and others.12,16–19,42 In this study, we demonstrated 
that LL-37 is a ligand for the major integrin receptor Mac-1 
(CD11b/CD18) on the surface of myeloid cells and found that 
coating of bacteria with LL-37 augments Mac-1-mediated 
Figure 8 Effect of LL-37 on phagocytosis of latex beads.
Notes: (A) Fluorescent latex beads (2.5×107/mL) were preincubated with LL-37 (10 mg/mL) for 20 minutes at 22°C. Soluble peptide was removed from beads by high-speed 
centrifugation. Peptide-coated beads were incubated with IC-21 cells, mouse peritoneal macrophages, or differentiated THP-1 cells for 30 minutes at 37°C. Nonphagocytosed 
beads were separated from macrophages by centrifugation. The ratio of beads per macrophage was quantified from three fields of fluorescent images. Data shown are mean 
± SE of triplicate measurements and are representative of three experiments. *P≤0.05 and **P≤0.01 compared with untreated beads. (B) Fluorescence of IC-21 macrophages 
exposed to LL-37-treated beads (a–c) or control untreated beads (e–g). Enlarged images of IC-21 macrophages showing phagocytosed LL-37-treated (d) or control (h) beads.
Abbreviation: SE, standard error.
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phagocytosis of both gram-negative and gram-positive bac-
teria. Importantly, LL-37 and its C-terminal K18-37 peptide 
enhanced phagocytosis at a range of concentrations that are 
not harmful to mammalian membranes. These observations 
establish a novel aspect of LL-37 action and suggest a role 
for this mechanism in the physiologic function of this host 
defense peptide.
The motivation to investigate the interaction of Mac-1 
with LL-37 was our recent finding that LL-37 binds the a
M
I-
domain, a ligand-binding region of Mac-1, induces a potent 
migratory response of Mac-1-expressing monocytes and 
macrophages, and activates Mac-1 on the surface of neutro-
phils.20 Integrin Mac-1 is a member of the b
2
 subfamily of leu-
kocyte integrin adhesion receptors and the major receptor on 
the surface of neutrophils and monocytes/macrophages. This 
receptor contributes to leukocyte adhesion to and diapedesis 
through the inflamed endothelium and controls leukocyte 
migration to sites of inflammation.40,41,43,44 Moreover, ligand 
engagement by Mac-1 initiates a variety of cellular responses, 
including phagocytosis, neutrophil degranulation and 
aggregation, expression of cytokines/ chemokines, and other 
pro- and anti-inflammatory molecules.40,41 Innumerable roles 
played by Mac-1 in leukocyte biology are thought to arise 
from its multiligand-binding properties. Indeed, this recep-
tor exhibits broad recognition specificity and is capable of 
binding an extremely diverse group of protein and nonprotein 
ligands.25 Screening a large number of the peptide libraries 
spanning the sequences of Mac-1 protein and peptide ligands 
for the a
M
I-domain binding has allowed us to determine the 
Mac-1 recognition motif(s).20 In particular, we found that the 
a
M
I-domain binds not to specific amino acid sequence(s) but 
rather has a preference for the sequence patterns consisting of 
a core of positively charged residues flanked by hydrophobic 
residues. Analyses of the LL-37 sequence showed that it 
contains several potential a
M
I-domain recognition cores, and 
this prediction was experimentally confirmed.20 Furthermore, 
in this study, we corroborated these data by synthesizing 
the library of the longer LL-37 derivative, FALL-39 (Figure 
1). The interaction of the a
M
I-domain with LL-37 was also 
recently reported by Zhang et al45 who used surface plasmon 
resonance and biolayer interferometry. Interestingly, no 
interaction of the a
M
I-domain with the 13-mer LL-37-derived 
Figure 9 Effect of LL-37 on phagocytosis of latex beads by Mac-1-deficient macrophages.
Notes: (A) Resident peritoneal macrophages were obtained from wild-type (WT) and Mac-1-/- mice. LL-37-coated beads were incubated with adherent macrophages 
for 30 minutes at 37°C. Nonphagocytosed beads were washed, cells treated with trypan blue, and the ratio of beads per macrophage was quantified from three fields of 
fluorescent images. Data shown are mean ± SE of triplicate measurements from three experiments. **P≤0.01 compared with untreated control beads. (B) Representative 
confocal image illustrates phagocytosed beads inside a macrophage. The representative fields of WT (C) and Mac-1-deficient (D) macrophages incubated with control and 
LL-37-coated beads. Bright field (a and d), fluorescence (b and e), and merged (c and f) images of WT and Mac-1-deficient macrophages.
Abbreviation: SE, standard error.
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peptide FKRIVQRIKDFLR (FK-13) was found.45 This result 
appears to conflict with our data showing that the shorter 
9-mer peptide FKRIVQRIK was the most active a
M
I-domain-
binding peptide in the library (Figure 1). This discrepancy 
may potentially arise from a high density of peptides within 
the spots in the library that would favor the interaction with 
the a
M
I-domain or other differences in the experimental 
format used. However, an alternative explanation, which is 
supported by our previous studies, may be that FK-13, in 
contrast to FKRIVQRIK, contains Asp. Indeed, we showed 
that negatively charged residues were strongly disfavored 
in the population of the a
M
I-domain-binding peptides.20 
Further studies of the LL-37-derived sequences and other 
Mac-1 ligands may help to define the binding specificity of 
the a
M
I-domain.
The role of LL-37 in combating bacterial assault has 
been shown in several models of infection6,45; however, the 
precise mechanism by which LL-37 exerts this protective 
effect has not been determined. Given its ability to directly 
kill pathogens in vitro, LL-37 was surmised to exert its effect 
by inserting into and disrupting the bacterial membrane. 
However, the validity of this mechanism in vivo has been 
questioned because the direct bactericidal activity was often 
observed only under low salt conditions and with relatively 
high concentrations of the peptide.6 In the presence of 
physiological salt concentrations and divalent cations, the 
antimicrobial activity of LL-37 was significantly reduced 
and in the presence of tissue culture medium, the peptide 
had no cytotoxic activity against S. aureus or Salmonella 
typhimurium even at concentrations as high as 100 mg/mL.6,9 
The high concentrations of LL-37 that are bactericidal in vitro 
have been detected in several locations during infection, for 
example, in bronchoalveolar lavage fluid.46 However, such 
concentrations would seem to not only kill bacteria but also 
damage neighboring host cells. In this regard, it was previ-
ously reported that LL-37 can affect membrane integrity.35,36 
Our finding that LL-37 at 10 mg/mL induced a small calcein 
leakage (~3-fold the background level of control untreated 
cells; data not shown) is in keeping with the harmful effect 
of high concentrations of the peptide on mammalian cells. 
While host cells may suffer during the bacterial attack, it is 
still difficult to imagine an expedient host defense mecha-
nism that turns not only on invaders but also on the host. 
The defense in which LL-37 spares host cells would seem 
by far more advantageous. From this perspective, the various 
immunomodulatory effects of LL-37 observed in standard 
tissue culture media or whole human blood in vitro6,9 may 
be a more rational explanation for its protective properties, 
especially in view of the modest concentrations of LL-37 in 
vivo. Furthermore, the process in which LL-37 marks the 
bacterial surface for recognition by macrophages to augment 
phagocytosis, as described in this study, would primarily tar-
get bacteria rather than host cells. It is well established that 
the differences in the lipid composition between prokaryotic 
and eukaryotic cell membranes, and in particular, the much 
higher concentration of negatively charged lipids on the 
surface of a bacterial cytoplasmic membrane and the pres-
ence of anionic lipids on the outer leaflet of gram-negative 
bacteria allow host defense peptides to preferentially interact 
with bacterial membranes.8,39 This property, however, may be 
mainly utilized to opsonize rather than kill bacteria. In this 
respect, it is worth noting that in this study, the concentra-
tions of LL-37 (1–5 mg/mL) that have been found to enhance 
bacterial phagocytosis were significantly lower than the 
minimal inhibitory concentrations (~30–100 mg/mL) required 
for bacterial killing in physiologically relevant buffers.6,47,48
LL-37 seems to be ideally suited to perform the opsonic 
function. First, its high positive charge (+6) facilitates the 
electrostatic interaction with negatively charged phospholipid 
headgroups of the bacterial surface.8 Second, when immo-
bilized on the bacterial surface, LL-37 serves as a ligand 
for Mac-1, a well-known phagocytic receptor.41,49 Third, the 
relatively small size of LL-37 would create a higher density 
on the bacterial surface compared with other known opsonins, 
for example, the complement pathway product iC3b, which 
is, intriguingly, another Mac-1 ligand.50 Fourth, it appears 
that numerous positively charged residues present in LL-37 
are involved in the interaction with macrophage HSPGs, 
which may strengthen the interaction with the LL-coated 
bacterial surface. It is worth noting, although, that the posi-
tive charge of the polypeptides on its own is not sufficient 
to induce phagocytosis. This idea is supported by the data 
that poly-l-lysine was not active in promoting phagocytosis 
 (Figure 6). This is consistent with the hypothesis that the 
specific interaction of LL-37 with Mac-1 is required to 
transduce a signal for phagocytosis.
The efficiency of bacterial phagocytosis critically depends 
upon the opsonization of pathogen as well as the state of 
macrophage activation. Previous studies reported that sev-
eral neutrophil-derived granule proteins/peptides opsonize 
bacteria resulting in enhanced phagocytosis.51,52 With regard 
to LL-37, it was shown that opsonization of oral Aggrega-
tibacter actinomycetemcomitans with the peptide resulted 
in increased phagocytosis by murine macrophages,53 and an 
uptake of LL-37-coated polystyrene beads by nondifferen-
tiated primary human monocytes was increased compared 
 
R
es
ea
rc
h 
an
d 
Re
po
rts
 in
 B
io
ch
em
ist
ry
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
9.
21
9.
8.
1 
on
 0
7-
Ju
l-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Research and Reports in Biochemistry 2016:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
52
Lishko et al
with uncoated beads.45 On the other hand, bacterial phago-
cytosis was also shown to be augmented by pretreatment of 
macrophages with neutrophil secretion products,54 including 
LL-37.27 In two latter studies, pretreatment of macrophages 
with the neutrophil secretion or with LL-37 was followed 
by their washing before addition of the bacteria; therefore, 
direct activation of macrophages was apparently responsible 
for enhanced phagocytosis. In our studies, we have used a 
reverse experimental format, that is, pretreatment of bacte-
ria with LL-37 followed by their extensive washing before 
addition to macrophages. Therefore, opsonization rather than 
activation was responsible for the increased phagocytosis. It 
is well established that prior activation of Mac-1 is required 
for its full phagocytic function.55 Therefore, the results of this 
study in conjunction with our previous findings showing that 
LL-37 activates Mac-1 on the surface of neutrophil20 suggest 
that LL-37 may play a dual role, that is, serving as an opsonin 
and as activator of Mac-1 on phagocytes.
The broad ligand-binding specificity exhibited by Mac-1 
and its affinity for peptides/proteins enriched in positively 
charged, and hydrophobic residues suggest that many other 
cationic defense proteins/peptides may fulfill the opsonic 
function through binding of Mac-1. Indeed, screening of 
several proteins stored in neutrophil granules as well as 
mammalian cathelicidins and other cationic peptides showed 
that they bind the a
M
I-domain20 (and unpublished data). 
Consistent with this proposal, we have recently shown that 
the cationic peptide dynorphin A that was previously shown 
to enhance phagocytosis56 opsonizes bacteria and promotes 
phagocytosis through Mac-1.57 Since negatively charged 
residues are generally strongly disfavored in the Mac-1 rec-
ognition motifs, it is tempting to speculate that the absence 
of negatively charged residues in some cathelicidin peptides 
(eg, bovine SMAP-29 and BMAP-271) as compared to LL-37 
may increase their Mac-1-binding activity. It is also possible 
that not only LL-37 but also its precursor hCAP-18 or its 
cathelin domain, which also contains putative Mac-1-binding 
sites, may increase phagocytosis. Further studies of Mac-1 
recognition motifs in cationic host defense peptides may help 
to determine whether they exhibit phagocytosis-promoting 
activity.
Considering the rapid emergence of bacterial strains 
resistant to conventional antibiotics and the exodus of 
many pharmaceutical companies from the field of antibiotic 
research and development, there has been an extensive effort 
to introduce host defense peptides, including LL-37, in clini-
cal practice for the treatment of infectious disease.58–60 As the 
development of therapeutics based on host defense peptides 
continues, it is important to gain a better understanding of 
every aspect of their action. Our finding that LL-37 is an 
opsonin, which boosts uptake of bacteria by macrophages via 
a specific engagement of the professional phagocytic receptor 
Mac-1, provides new insights into the role of this peptide in 
host defense, but also leaves many questions. Resolving the 
problems of how the opsonic function of LL-37 is coordinated 
with other known activities of this peptide and the question 
whether other cationic proteins/peptides fulfill the phagocytic 
function via Mac-1 and if so, what is their relative potency, 
would be of particular interest.
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Figure S1 Correlation between adhesion of Mac-1-expressing cells to immobilized 
LL-37-GY and the surface density of plastic-bound LL-37-GY. Various concentrations 
of l25I-labeled LL-37-GY were immobilized on wells of 96-well microtiter plates 
under the same conditions used for adhesion assays.
Notes: The plates were washed and bound radioactivity was measured in a 
g-counter. Right ordinate shows cpm/well (o) and left ordinate shows fluorescence 
of cells adherent to wells (·) coated with LL-37-GY.
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